Ac-SDKP (TB4 Fragment 1-4): The Anti-Fibrotic Tetrapeptide

Ac-SDKP — N-acetyl-Ser-Asp-Lys-Pro — is the N-terminal tetrapeptide fragment of thymosin beta-4. It is naturally occurring, has documented anti-fibrotic activity in animal models, and connects unexpectedly to one of the most widely prescribed drug classes in medicine.

This guide situates Ac-SDKP (TB4 Fragment 1-4) within the broader field of peptide therapy and is written for clinicians. It is clinical education, not medical advice, and nothing here should be read as a treatment recommendation or protocol.

What is Ac-SDKP?

Ac-SDKP is a tetrapeptide of four amino acids, released from the N-terminal region of thymosin beta-4 through the action of prolyl oligopeptidase. It circulates naturally in human plasma at measurable concentrations.

The important conceptual point is that a peptide fragment can carry activity that is not simply a weaker version of the parent. Thymosin beta-4 is best known for actin binding, cell migration and tissue repair. Ac-SDKP's characterized activity is anti-fibrotic and hematopoietic-regulatory — a distinct profile. The same principle appears with GHRH(1-29) and other fragments, and it is a reason not to assume a fragment behaves like its parent.

The anti-fibrotic evidence

In animal models of cardiac, renal and pulmonary fibrosis, Ac-SDKP has been shown to reduce collagen deposition and fibroblast proliferation, with effects on inflammatory cell infiltration.

Mechanistically, the work points to interference with TGF-beta signaling — the central fibrotic pathway. Ac-SDKP appears to inhibit TGF-beta-driven SMAD activation and downstream matrix production.

This is a coherent and reasonably well-supported preclinical story. It is also, importantly, animal-model evidence. It has not been translated into an approved human therapy, and the gap between reducing fibrosis in a rodent model and improving outcomes in human fibrotic disease has defeated many candidates.

Ac-SDKP also acts as a physiologic inhibitor of hematopoietic stem cell proliferation, which is a separate biological role and a reminder that it is not a single-purpose molecule.

Why ACE inhibitors raise Ac-SDKP

The most clinically interesting fact about Ac-SDKP is its metabolism. It is hydrolyzed by angiotensin-converting enzyme — the same ACE that converts angiotensin I to angiotensin II.

ACE is not a single-substrate enzyme. It degrades bradykinin, which is why ACE inhibitors cause cough, and it degrades Ac-SDKP. The consequence is direct: patients taking an ACE inhibitor have substantially elevated Ac-SDKP levels, several-fold above baseline.

This has generated a genuinely interesting hypothesis. ACE inhibitors have long been observed to provide organ protection — renal and cardiac — that appears to exceed what blood pressure reduction alone would predict. Elevated Ac-SDKP, with its anti-fibrotic activity, has been proposed as one contributor to that effect.

The hypothesis is plausible and not established. But it illustrates something worth carrying: peptide biology is often already being modulated by drugs in routine use, without that being how the drug is described.

Status

Ac-SDKP is not an approved therapy and is not an established compounding substance. Material sold under this name is unregulated research chemical.

The practical clinical takeaway is not a product recommendation. It is that a patient with fibrotic or hypertensive cardiac or renal disease already has an evidence-based, approved intervention that raises this peptide as part of its effect — and that intervention is an ACE inhibitor, prescribed on the basis of outcome trials rather than mechanism.